These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34580915)

  • 1. Pembrolizumab-induced benign atypical intralymphatic CD30
    Hung WK; Chen CB; Kuo TT; Chen WT
    J Dermatol; 2022 Feb; 49(2):e53-e54. PubMed ID: 34580915
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralymphatic CD30+ T-cell proliferation during DRESS: a mimic of intravascular lymphoma.
    Weingertner N; Mitcov M; Chenard MP; Cribier B
    J Cutan Pathol; 2016 Nov; 43(11):1036-1040. PubMed ID: 27433889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign atypical intravascular CD30+ T-cell proliferation: a recently described reactive lymphoproliferative process and simulator of intravascular lymphoma: report of a case associated with lichen sclerosus and review of the literature.
    Kempf W; Keller K; John H; Dommann-Scherrer C
    Am J Clin Pathol; 2014 Nov; 142(5):694-9. PubMed ID: 25319987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign atypical intralymphatic CD30+ lymphoid proliferation with activated regulatory T-cell phenotype in the oral cavity.
    Ferrisse TM; Almeida LY; Silveira HA; de Oliveira AB; Bufalino A; León JE
    J Cutan Pathol; 2019 Nov; 46(11):891-894. PubMed ID: 31237706
    [No Abstract]   [Full Text] [Related]  

  • 5. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
    Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
    Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Intravascular Hematolymphoid Entities: A Review.
    Marshall EH; Brumbaugh B; Holt A; Chen ST; Hoang MP
    Diagnostics (Basel); 2024 Mar; 14(7):. PubMed ID: 38611591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign atypical intravascular CD30(+) T-cell proliferation: a reactive condition mimicking intravascular lymphoma.
    Riveiro-Falkenbach E; Fernández-Figueras MT; Rodríguez-Peralto JL
    Am J Dermatopathol; 2013 Apr; 35(2):143-50. PubMed ID: 23542715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralymphatic Proliferation of T-cell Lymphoid Blasts in the Setting of Hidradenitis Suppurativa.
    Calamaro P; Cerroni L
    Am J Dermatopathol; 2016 Jul; 38(7):536-40. PubMed ID: 26844617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous intralymphatic CD30
    Gralewski J; Post GR
    Blood; 2018 Oct; 132(17):1859. PubMed ID: 30361464
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravascular Cutaneous Disorders. A Clinicopathologic Review.
    Vilas Boas P; Cerroni L; Requena L
    Am J Dermatopathol; 2021 Feb; 43(2):119-136. PubMed ID: 32618704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
    Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
    Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates.
    Ralfkiaer E; Bosq J; Gatter KC; Schwarting R; Gerdes J; Stein H; Mason DY
    Arch Dermatol Res; 1987; 279(5):285-92. PubMed ID: 2820316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma.
    Kinney MC; Collins RD; Greer JP; Whitlock JA; Sioutos N; Kadin ME
    Am J Surg Pathol; 1993 Sep; 17(9):859-68. PubMed ID: 8394652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and a role of CD30 in regulation of T-cell activity.
    Tarkowski M
    Curr Opin Hematol; 2003 Jul; 10(4):267-71. PubMed ID: 12799531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.
    Gruss HJ; Boiani N; Williams DE; Armitage RJ; Smith CA; Goodwin RG
    Blood; 1994 Apr; 83(8):2045-56. PubMed ID: 8161776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
    Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
    Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
    Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.